Telehealth sees rising off-label use of GLP-1s for substance abuse
Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag…
NVO’s Ozempic Outshines LLY’s Mounjaro in Lowering Cardiovascular Risk
Novo NVO announced new real-world data from the COMPETE SWITCH Cardiovascular (CV) study comparing treatment strategies in adults…
The reason your healthcare premiums are skyrocketing? AI.
Rising healthcare costs are hammering Americans, and now artificial intelligence is raising the price tag even more. The…
This Biotech Company Added Nearly $3B To Its Market Cap – Here’s Why KOD Stock Is Ripping Today
Zenkuda and Tabirafusp-ted produced vision improvements that were statistically non-inferior to Aflibercept, an established treatment for the eye…
Veteran doctor reveals how faith can help patients
Dr. Marc Siegel, physician and Fox News senior medical analyst, explores the intersection of spirituality, clinical treatment and…
Does exercise make botox wear off faster? Here are doctors’ opinions
Could intense exercise burn off Botox injections along with calories? Smooth-faced citizens are wondering if neurotoxins like Botox…
What ‘Asian glow’ means for patients’ long-term health and drinking
I was 8 years old, sitting at dinner with my grandparents, watching Gong Gong’s face turn bright red…
Doctors Share The Habits They Changed After Seeing Patients Suffer
People who work in medical professions, like doctors, nurses, and EMTs, often see firsthand what can happen to…
The new GLP-1 weight-loss pill vs. the shot: a doctor’s answer on oral Wegovy
FDA approved the Wegovy pill, the first oral semaglutide for weight management, in late December 2025, and it…
How to write a patient portal message so your doctor responds
Is your doctor leaving you on read? A new study suggests that the secret to getting your provider…
Mass General Brigham Medicare Advantage plan drops Dana-Farber
Eldon Clingan has had the same cancer specialist at Dana-Farber Cancer Institute for more than two decades. He…
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS…